CAN-FITE REPORTS DATA FROM DRY EYE STUDY
Can-Fite BioPharma has reported new clinical data demonstrating activity of CF101 in improving dry eye symptoms in human patients suffering from keratitis sicca (know also as keratoconjunctivitis sicca).
Keratitis sicca is a chronic eye disease that results from inadequate tear volume, leading to eye irritation that may lead to temporary or rarely permanent impairment in vision. It is a disease that is commonly found in rheumatoid arthritis (RA) patients. Dry eye symptoms of several RA patients that participated in the compnany's Phase IIa study and that also suffered from keratitis sicca were significantly improved following treatment with CF101.